SCHEMBL3561569

SCHEMBL3561569

COC(=O)c1ccc(N2CCN(c3cccc(Cc4ccccc4)c3)C2=O)c(F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.47
CYP1A2 P05177 3/20 0.40
CYP3A4 P08684 3/20 0.40
CTSG P08311 2/20 0.40
CMA1 P23946 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
MAPT P10636 3/20 0.40
HPGD P15428 1/20 0.40
HTR7 P34969 1/20 0.39
SMN1; SMN2 Q16637 4/20 0.38
ALDH1A1 P00352 2/20 0.38
HSD17B10 Q99714 1/20 0.38
POLB P06746 1/20 0.38
CACNA2D1 P54289 1/20 0.38
NTRK1 P04629 1/20 0.38
KDM4E B2RXH2 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14423072 0.84 MAPT (0.48) NPC1CYP1A2CYP3A4CTSGCMA1
SCHEMBL3560047 0.83 NPC1 (0.45) NPC1CYP1A2CYP3A4CTSGCMA1
SCHEMBL3559364 0.83 NPC1 (0.45) NPC1CYP1A2CYP3A4CTSGCMA1
SCHEMBL13185180 0.82 MEN1 (0.41) NPC1CYP3A4KMT2AMEN1MAPT
SCHEMBL3556370 0.81 CFTR (0.43) NPC1KMT2AMEN1MAPTHTR7
SCHEMBL3553984 0.79 ALDH1A1 (0.44) NPC1CYP1A2CYP3A4CYP2C19KMT2A
SCHEMBL3559981 0.78 NPC1 (0.41) NPC1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL3559417 0.78 HDAC1 (0.51) NPC1CTSGCMA1KMT2AMEN1
SCHEMBL3554073 0.76 S1PR1 (0.58)
SCHEMBL2069334 0.71 LOXL2 (0.68) MAPTHPGDSMN1; SMN2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317649-A1 S1P Receptor Modulating Compounds and Use Thereof EPIX PHARMACEUTICALS, INC. (US) 2010-12-16 US disclosed
US-20100317649-A1 S1P Receptor Modulating Compounds and Use Thereof EPIX PHARMACEUTICALS, INC. (US) 2010-12-16 US disclosed
US-7790707-B2 S1P receptor modulating compounds and use thereof EPIX PHARMACEUTICALS INC. (US) 2010-09-07 US disclosed
US-7790707-B2 S1P receptor modulating compounds and use thereof EPIX PHARMACEUTICALS INC. (US) 2010-09-07 US disclosed
US-20080015177-A1 S1P receptor modulating compounds and use thereof AMGEN INC. 2008-01-17 US disclosed
US-20080015177-A1 S1P receptor modulating compounds and use thereof AMGEN INC. 2008-01-17 US disclosed
WO-2007109330-A2 S1P RECEPTOR MODULATING COMPOUNDS EPIX DELAWARE, INC. (US) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015177-A1 S1P receptor modulating compounds and use thereof S1PR1, S1PR2, S1PR5 NPC1 531/4885CYP1A2 2956/4885CYP3A4 3531/4885
US-20100317649-A1 S1P Receptor Modulating Compounds and Use Thereof S1PR1, S1PR2, S1PR5 NPC1 531/4885CYP1A2 2956/4885CYP3A4 3531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.